It is focusing on retinal diseases, with its most advanced programme AGTC-501 for X-linked retinitis pigmentosa (XLRP), which is in the phase 2/3 VISTA trial. AGTC-501 is vying to become the first ...

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM ...

Using synthetic data generated via conditioning with disease labels can enhance the pretraining efficiency and generalization of medical foundation models, as shown for the detection of eye ...

Left atrial pressure normalisation by graded radiofrequency atrial septostomy in heart failure with preserved ejection fraction: a single-arm pilot study ...